U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07288398) titled 'LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2' on Dec. 15.
Brief Summary: The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) as measured by the change in 6-Minute Walk Distance.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Pulmonary Hypertension Associated With HFpEF
Intervention:
DRUG: TNX-103
Oral levosimendan
DRUG: Placebo
Matching placebo (oral)
Recruitment Statu...